How to buy rights to abandoned pharma compounds

The pharmaceutical industry is littered with abandoned assets. Large pharma companies routinely halt clinical trials for promising compounds not because they lack efficacy, but due to shifting strategic priorities or minor side effects that don’t fit their blockbuster drug portfolio. For nimble biotech startups, these abandoned pharmaceutical compounds represent a goldmine of potential, especially for drug repurposing or treating rare diseases.

However, the traditional process of acquiring the intellectual property (IP) for these shelved compounds is notoriously difficult. It involves years of legal negotiation, opaque pricing, and complex royalties. Big pharma simply doesn’t have the time to negotiate small IP transfers.

Digital Patent AI revolutionizes this process by transforming abandoned pharma compounds into tradable digital assets through blockchain tokenization.

Tokenizing abandoned pharmaceutical assets

Our platform allows large pharmaceutical companies to securely package the patents, chemical structures, and historical clinical trial data of shelved compounds into Real World Assets (RWAs). We utilize a dual-token smart contract architecture:

1. Non-Exclusive Tokens: Pharma companies can issue digital licenses allowing research institutions to access the data for academic studies.
2. Exclusive Token: A single token representing the absolute, exclusive buyout of the compound’s intellectual property and commercialization rights.

This tokenized approach creates a liquid market for pharmaceutical IP, bypassing the slow, expensive, and opaque traditional legal framework.

Securing the Exclusive Token for commercialization

When a biotech startup identifies a promising abandoned compound on our platform that fits their research pipeline, they don’t need to hire a team of IP lawyers. They can simply purchase the Exclusive Token.

The moment this transaction occurs, our smart contract enforces strict algorithmic protection. The issuance of any new non-exclusive data licenses is permanently blocked. The biotech startup instantly secures total, exclusive control over the compound, preventing competitors from acquiring the same asset.

A frictionless, royalty-free market

Traditional IP acquisitions in biotech are plagued by milestone payments and ongoing royalty demands that drain a startup’s future revenue. Digital Patent AI eliminates this burden. We charge a flat 2.5% platform commission solely on the primary sale of the token. There are no hidden fees, no milestone payments, and absolutely no continuous royalties.

Furthermore, our proprietary AI matching system acts as an automated tech scout. It instantly connects the specific research focuses of biotech startups with the exact tokenized compounds available from large pharmaceutical companies.

Stop wasting years negotiating with big pharma. Buy exclusive rights to abandoned pharma compounds instantly with Digital Patent AI.